News
04/19/2024
ivWatch prevents IV leakage events at Frimley Health
Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous …
04/17/2024
U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning. …
04/15/2024
Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship
Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them …
04/10/2024
Phlow kicks off drug ingredient production in Petersburg
A local pharma company and player in a regional effort to build a pharmaceutical hub in Central Virginia has started manufacturing operations. Richmond-based Phlow Corp. recently began manufacturing ingredients used in medicines at a facility at 2818 N. Normandy Drive in Petersburg, according to Robby Demeria, the company’s chief corporate affairs officer. The 19,200-square-foot facility …
04/03/2024
TearSolutions, Inc. Appoints Dr. Louis M Alpern to its Board of Directors
TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED) and other ocular surface related diseases, today announced that Louis M Alpern, MD, MPH, FACS, FICS has been appointed to the Company’s Board of Directors. “Dr. Alpern brings extensive real-world clinical experience treating patients with ocular …
03/28/2024
ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure …
03/28/2024
AMPEL BioSolutions’ Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus. Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI. The LuGENE® lab test is now launching at …